Expecting price to correct upwards between $13.73 and $16.49 in minor C followed by intermediate (C) in ((2)) to between the 61.8% or the 85.4% trend based fib extension. Invalid below 0.5525 cents.
GSK is trading around the multi year lows having bounced off of the long term support zone at 1300. I think this is a relative bargain at these levels with GSK being one of the Big Pharma Companies that is still trading way below the starting price for the year.
Pfizer, Johnson & Johnson and Roche are all either positive or around net zero YTD. Novartis is...
$NEWT is one of the stocks we monitor in our income stock watchlist. I like how it's setting up for a buy here, normally it falls after going ex-dividend, since investors leg into it ahead of the dividend being paid, and exit after receiving it. This is a reliable pattern in this stock.
Technicals show price met a downtrend target slightly ahead of time, and as...
